×
About 640 results

ALLMedicine™ Bullous Diseases Center

Research & Reviews  319 results

The role of T cells in pemphigus vulgaris and bullous pemphigoid.
https://doi.org/10.1016/j.autrev.2020.102661
Autoimmunity Reviews; Fang H, Li Q et. al.

Sep 17th, 2020 - Pemphigus vulgaris (PV) and bullous pemphigoid (BP) are autoantibody-mediated diseases clinically characterized by blistersanderosions of skin and/or mucous membranes. Immune imbalance and antibody generation are the key pathologies of autoimmune ...

Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated ...
https://doi.org/10.1111/jdv.16752
Journal of the European Academy of Dermatology and Venereology : JEADV References; Joly P, Horwath B et. al.

Aug 23rd, 2020 - Pemphigus encompasses a group of life-threatening autoimmune bullous diseases characterized by blisters and erosions of the mucous membranes and skin. Before the era of immunosuppressive treatment, pemphigus was almost always fatal. Due to its rar...

COVID-19 outbreak and autoimmune bullous diseases: A systematic review of published cases.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7414356
Journal of the American Academy of Dermatology; Kasperkiewicz M

Aug 11th, 2020 - COVID-19 outbreak and autoimmune bullous diseases: A systematic review of published cases.|2020|Kasperkiewicz M,|

Rituximab in childhood and juvenile autoimmune bullous diseases as first-line and secon...
https://doi.org/10.1080/09546634.2020.1788702
The Journal of Dermatological Treatment; Kianfar N, Dasdar S et. al.

Jun 26th, 2020 - Little data are available concerning the outcome of rituximab (RTX) therapy in pediatric patients with autoimmune bullous diseases (AIBDs). We sought to evaluate safety and efficacy of RTX administration in pediatric patients with AIBDs and to ass...

Rituximab in autoimmune pemphigoid diseases: Indications, optimized regimens, and pract...
https://doi.org/10.1016/j.clindermatol.2019.07.023
Clinics in Dermatology; Thomas RM, Colon A et. al.

Jun 21st, 2020 - Rituximab is a monoclonal antibody targeting CD20 on B cells with proven efficacy for pemphigus vulgaris, now an FDA-approved indication. Other autoimmune bullous diseases can be challenging to treat and have significant associated morbidity and m...

see more →

Guidelines  1 results

Pemphigus. S2 Guideline for diagnosis and treatment--guided by the European Dermatology...
https://doi.org/10.1111/jdv.12772
Journal of the European Academy of Dermatology and Venereology : JEADV; Hertl M, Jedlickova H et. al.

Oct 23rd, 2014 - Pemphigus encompasses a group of life-threatening autoimmune bullous diseases characterized by blisters and erosions of the mucous membranes and skin. Before the era of immunosuppressive treatment, the prognosis of pemphigus was almost fatal. Due ...

see more →

Clinicaltrials.gov  319 results

The role of T cells in pemphigus vulgaris and bullous pemphigoid.
https://doi.org/10.1016/j.autrev.2020.102661
Autoimmunity Reviews; Fang H, Li Q et. al.

Sep 17th, 2020 - Pemphigus vulgaris (PV) and bullous pemphigoid (BP) are autoantibody-mediated diseases clinically characterized by blistersanderosions of skin and/or mucous membranes. Immune imbalance and antibody generation are the key pathologies of autoimmune ...

Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated ...
https://doi.org/10.1111/jdv.16752
Journal of the European Academy of Dermatology and Venereology : JEADV References; Joly P, Horwath B et. al.

Aug 23rd, 2020 - Pemphigus encompasses a group of life-threatening autoimmune bullous diseases characterized by blisters and erosions of the mucous membranes and skin. Before the era of immunosuppressive treatment, pemphigus was almost always fatal. Due to its rar...

COVID-19 outbreak and autoimmune bullous diseases: A systematic review of published cases.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7414356
Journal of the American Academy of Dermatology; Kasperkiewicz M

Aug 11th, 2020 - COVID-19 outbreak and autoimmune bullous diseases: A systematic review of published cases.|2020|Kasperkiewicz M,|

Rituximab in childhood and juvenile autoimmune bullous diseases as first-line and secon...
https://doi.org/10.1080/09546634.2020.1788702
The Journal of Dermatological Treatment; Kianfar N, Dasdar S et. al.

Jun 26th, 2020 - Little data are available concerning the outcome of rituximab (RTX) therapy in pediatric patients with autoimmune bullous diseases (AIBDs). We sought to evaluate safety and efficacy of RTX administration in pediatric patients with AIBDs and to ass...

Rituximab in autoimmune pemphigoid diseases: Indications, optimized regimens, and pract...
https://doi.org/10.1016/j.clindermatol.2019.07.023
Clinics in Dermatology; Thomas RM, Colon A et. al.

Jun 21st, 2020 - Rituximab is a monoclonal antibody targeting CD20 on B cells with proven efficacy for pemphigus vulgaris, now an FDA-approved indication. Other autoimmune bullous diseases can be challenging to treat and have significant associated morbidity and m...

see more →

News  1 results

Pemphigus Foliaceus: A Case Report and Short Review
https://www.mdedge.com/dermatology/article/67396/contact-dermatitis/pemphigus-foliaceus-case-report-and-short-review
Khachemoune A, Guldbakke KK et. al.

Pemphigus describes a group of autoimmune chronic bullous diseases, originally named in 1791. 1 The term pemphigus stems from the Greek pemphix meaning blister or bubble.

see more →